Novartis Ag (NVS) Research & Development (2009 - 2025)
Novartis Ag recorded quarterly Research & Development of -$2.7 billion in Q2 2025, up 43.05% quarter-over-quarter from -$4.8 billion in Q4 2024, and down 15.21% year-over-year from -$3.2 billion in Q2 2024.
Novartis Ag's Research & Development history runs 16 years deep, the most recent figure standing at -$2.7 billion for Q2 2025.
- In Q2 2025, Research & Development fell 15.21% year-over-year to -$2.7 billion; the TTM figure through Jun 2025 stood at -$14.8 billion (down 51.1% YoY), while the FY2025 annual figure was $11.2 billion, up 11.75% from the prior year.
- Research & Development came in at -$2.7 billion for Q2 2025 at Novartis Ag, up from -$4.8 billion in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$194.0 million in Q3 2022 to a low of -$4.9 billion in Q4 2023.
- A 5-year average of -$1.8 billion and a median of -$1.3 billion in 2021 frame the typical range for Research & Development.
- On a YoY basis, Research & Development climbed as much as 52.18% in 2023 and fell as far as 2058.85% in 2023.
- Novartis Ag's Research & Development stood at -$240.0 million in 2021, then climbed by 5.83% to -$226.0 million in 2022, then tumbled by 2058.85% to -$4.9 billion in 2023, then rose by 1.87% to -$4.8 billion in 2024, then jumped by 43.05% to -$2.7 billion in 2025.
- According to Business Quant data, Research & Development over the past three periods registered -$2.7 billion, -$4.8 billion, and -$2.4 billion for Q2 2025, Q4 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.73 Bn |
| Dec 31, 2024 | -4.79 Bn |
| Jun 30, 2024 | -2.37 Bn |
| Dec 31, 2023 | -4.88 Bn |
| Jun 30, 2023 | -2.30 Bn |
| Mar 31, 2023 | -219.00 Mn |
| Dec 31, 2022 | -226.00 Mn |
| Sep 30, 2022 | -194.00 Mn |
| Jun 30, 2022 | -4.82 Bn |
| Mar 31, 2022 | -208.00 Mn |
| Dec 31, 2021 | -240.00 Mn |
| Sep 30, 2021 | -224.00 Mn |
| Jun 30, 2021 | -2.40 Bn |
| Mar 31, 2021 | -214.00 Mn |
| Dec 31, 2020 | -251.00 Mn |
| Sep 30, 2020 | -216.00 Mn |
| Jun 30, 2020 | -2.44 Bn |
| Mar 31, 2020 | -194.00 Mn |
| Mar 31, 2019 | -194.00 Mn |
| Dec 31, 2018 | -224.00 Mn |
| Sep 30, 2018 | -196.00 Mn |
| Jun 30, 2018 | -2.28 Bn |
| Mar 31, 2018 | -199.00 Mn |
| Dec 31, 2017 | -198.00 Mn |
| Sep 30, 2017 | -195.00 Mn |
| Jun 30, 2017 | -2.06 Bn |
| Mar 31, 2017 | -186.00 Mn |
| Dec 31, 2016 | 9.64 Bn |
| Sep 30, 2016 | -204.00 Mn |
| Jun 30, 2016 | -206.00 Mn |
| Mar 31, 2016 | -195.00 Mn |
| Dec 31, 2015 | -242.00 |
| Sep 30, 2015 | -191.00 Mn |
| Mar 31, 2015 | -196.00 |
| Dec 31, 2014 | -247.00 |
| Sep 30, 2014 | -215.00 |
| Mar 31, 2014 | -232.00 |
| Sep 30, 2012 | -250.00 |
| Jun 30, 2012 | -248.00 |
| Mar 31, 2012 | -248.00 |
| Dec 31, 2011 | -237.00 |
| Sep 30, 2011 | -231.00 |
| Jun 30, 2011 | -214.00 |
| Mar 31, 2011 | -210.00 |
| Dec 31, 2010 | -222.00 |
| Sep 30, 2010 | -135.00 |
| Jun 30, 2010 | -159.00 |
| Mar 31, 2010 | -2,037.00 |
| Dec 31, 2009 | -7.47 Bn |
| Sep 30, 2009 | -1,825.00 |
| Jun 30, 2009 | -1,802.00 |
| Mar 31, 2009 | -1,694.00 |